Study of aphrodisiac activity of HARSH-6 on Erectile Dysfunction

Pharmaceutico Therapeutic Study of HARSH 6 as Vajikaran

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041891

Enrollment

120

Registered

2022-04-18

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N529- Male erectile dysfunction, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: male married patients suffering from klaibya(ED) and Premature ejaculation

Exclusion criteria

Exclusion criteria: Age below 21 and above 50 years, unmarried patient, patient suffering from STD, CARCINOMA, AIDS, congenital anomalies of genital organs, other diseases like phymosis, ulceration, hydrocoel, spinal cord lesion etc

Design outcomes

Primary

Measure	Time frame
Extent of Penile erection, penile rigidity, penile pain during act, duration of sexual desire, ejaculation, orgasm, performance anxiety, post act exhaustion etc. the subjective parameters will be designed as per International Index of Erectile Dysfunction( grading score pattern). Complete Blood Count, Routine Semen Analysis, Urine Analysis, Blood sugar (FBS/PPBS), Serum cholesterol, Testosterone level, RFT, LFT will be done before the treatment and at the end of trial treatment. Timepoint: BASELINE, 4 WEEK, 8 WEEK AND 12 WEEK. The follow up at 12v week will be treated as final.	—

Measure

Time frame

Extent of Penile erection, penile rigidity, penile pain during act, duration of sexual desire, ejaculation, orgasm, performance anxiety, post act exhaustion etc. the subjective parameters will be designed as per International Index of Erectile Dysfunction( grading score pattern). Complete Blood Count, Routine Semen Analysis, Urine Analysis, Blood sugar (FBS/PPBS), Serum cholesterol, Testosterone level, RFT, LFT will be done before the treatment and at the end of trial treatment. Timepoint: BASELINE, 4 WEEK, 8 WEEK AND 12 WEEK. The follow up at 12v week will be treated as final.

—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactShakti Bhushan

Banaras Hindu University

anandayubhu@gmail.com9452074480

Outcome results